ADMS News and Press, Adamas Pharmaceuticals Inc. From 01/09/20

5 Penny Stocks On Robinhood To Watch This Month Investing in penny stock can often prove to be the most rewarding class of stocks for investors. Why? Over the years, these stocks have generated a lot of wealth for investors, quickly. One of the most important things that need to be pointed o...

Gainers: ShiftPixy (NASDAQ: PIXY ) +162% . More news on: ShiftPixy, Inc., Wah Fu Education Group Limited, Verastem, Inc., Stocks on the move, Read more ...

On a preliminary basis , Adamas Pharmaceuticals ( ADMS +10.3% ) expects Gocovri (amantadine) sales in Q4 and 2019 to be ~$16.3M (+23%) and ~$54.6M (+61%), respectively. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

-- Product sales expected to be approximately $16.3 million for fourth quarter 2019 and approximately $54.6 million for full year 2019 -- -- Total prescriptions of approximately 7,160 for fourth quarter 2019 and approximately 25,780 for full year 2019 -- EMERYVILLE, Calif., Jan. 08...

EMERYVILLE, Calif., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a ...

Adamas Pharmaceuticals ( ADMS ) publicized their INROADS study in multiple sclerosis “MS” patients with walking impairment met its primary endpoint but missed on its secondary endpoints. The results exhibited that patients taking 274 mg of GOCOVRI had a statistically significant ...

New York, New York--(Newsfile Corp. - December 17, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) ("Adamas" or the "Company") of the February 10, 2020 deadline to seek the role of lead plaintiff in a fe...

Gainers:  Kaixin Auto (NASDAQ: KXIN ) +32% . More news on: Kaixin Auto Holdings, NantKwest, Inc., Renewable Energy Group, Inc., Stocks on the move, Read more ...

Adamas Pharmaceuticals ( ADMS -39.9% ) slumps on a 5x surge in volume as investors scrutinize the Phase 3 results on Gocovri (amantadine) released this morning. More news on: Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

"As we did not see the scale of clinical benefit we had hoped for in this study we will fully assess the potential for ADS-5102 in MS patients before determining the extent of our continued investment in this program," says Adamas ( ADMS -40.7% ) CEO Neil McFarlane after mixed results in...